Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EG6 | ISIN: FI4000571054 | Ticker-Symbol: XK2
Frankfurt
21.01.25
15:29 Uhr
29,600 Euro
+0,040
+0,14 %
Branche
Maschinenbau
Aktienmarkt
Sonstige
1-Jahres-Chart
KALMAR OYJ Chart 1 Jahr
5-Tage-Chart
KALMAR OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
30,28031,30021.01.
30,68030,96021.01.
GlobeNewswire (Europe)
308 Leser
Artikel bewerten:
(2)

Kalmar Corporation: Shareholders' Nomination Board's proposals regarding the composition and remuneration of Kalmar's Board of Directors

Finanznachrichten News

KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 5 DECEMBER 2024 AT 14:30 PM (EET)

Shareholders' Nomination Board's proposals regarding the composition and remuneration of Kalmar's Board of Directors

The Shareholders' Nomination Board

All the Board member candidates have given their consent to be elected and have been assessed to be independent of the company and its significant shareholders.

With regard to the selection procedure for the members of the Board of Directors, the Shareholders' Nomination Board recommends that shareholders take a position on the proposal as a whole at the General Meeting. This recommendation is based on the fact that in Kalmar Corporation, in line with a good Nordic governance model, the Shareholders' Nomination Board is separate from the Board of Directors. The Shareholders' Nomination Board, in addition to ensuring that individual nominees for membership of the Board of Directors possess the required competencies, is also responsible for making sure that the proposed Board of Directors as a whole has the best possible expertise and experience for the Company and that the composition of the Board of Directors meets other requirements of the Finnish Corporate Governance Code for listed companies.

The Nomination Board proposes fixed annual remuneration to the Board members as follows:

  • Chair of the Board: EUR 160,000 (EUR 160,000 in 2024)
  • Vice Chair of the Board: EUR 95,000 (EUR 95,000 in 2024)
  • Other members of the Board: EUR 80,000 (EUR 80,000 in 2024)

An additional fixed remuneration is proposed to be paid to the Board members that are elected as members of committees as follows:

  • Chair of the Audit and Risk Management Committee: EUR 20,000 (EUR 20,000 in 2024)
  • Member of the Audit and Risk Management Committee: EUR 10,000 (EUR 10,000 in 2024)
  • Chair of the Personnel and Remuneration Committee: EUR 15,000 (EUR 15,000 in 2024)
  • Member of the Personnel and Remuneration Committee: EUR 10,000 (EUR 10,000 in 2024)
  • Chair of any other committee possibly constituted by the Board in accordance with a separate decision by the Board: EUR 15,000 (maximum EUR 15,000 in 2024)
  • Member of any other committee constituted by the Board: EUR 5,000 (EUR 5,000 in 2024)

In addition to the fixed annual fee, a meeting fee of EUR 1,000 would be paid to the Board member participating in a Board or Committee meeting when the meeting takes place in the member's country of residence. For meetings held in a different country than where the Board member is domiciled, the meeting fee would be EUR 2,000 and for meetings held on a different continent than where the Board member is domiciled, the meeting fee would be EUR 3,000. For remote and telephone meetings or when attending a regular meeting remotely, the meeting fee would be EUR 1,000.

Approximately 40% of the fixed yearly remuneration would be paid in Kalmar's class B shares and the rest in cash. The aim is that the purchase of the shares from the market at a price formed in public trading would be commenced after the Q1 2025 interim result publication. The company would cover the transfer taxes related to the remuneration paid in shares.

The expenses of Board members related to travel and accommodation as well as other costs directly related to board and committee work would be reimbursed in accordance with Kalmar's policies.

The Nomination Board consists of four (4) members. According to the Charter of the Nomination Board, the members of the Nomination Board are appointed as follows: the two largest shareholders of class A shares are entitled to appoint one (1) member each, and the two largest shareholders of class B shares who do not own any class A shares, are entitled to appoint one (1) member each.

According to the Charter of the Nomination Board, the number of votes held by each shareholder of all shares in the Company are determined based on the shareholders' register of Kalmar as per the situation on the first banking day of June each year. As Kalmar was not established until the completion of the demerger on 30 June 2024, the right to appoint members to the Nomination Board was determined based on Cargotec Corporation's shareholders' register as per the situation on the first banking day of June, i.e., 3 June 2024. In the demerger of Cargotec, the shareholders of Cargotec received as demerger consideration one (1) new share of the corresponding share class (i.e., class A or class B) in Kalmar for each class A and each class B share they held in Cargotec.

In accordance with the above, the members of Kalmar's Nomination Board are:

  • Ilkka Herlin (appointed by Wipunen varainhallinta oy)
  • Heikki Herlin (appointed by Mariatorp Oy)
  • Mikko Mursula, Deputy CEO, Investments, Ilmarinen Mutual Pension Insurance Company (appointed by Ilmarinen Mutual Pension Insurance Company)
  • Carl Pettersson, CEO, Elo Mutual Pension Insurance Company (appointed by Elo Mutual Pension Insurance Company).

In accordance with the Charter of the Nomination Board, the Chair of Kalmar's Board of Directors participates in the Nomination Board's work as an expert without having the right to participate in the decision-making of the Nomination Board.

For further information, please contact:
Carina Geber-Teir, SVP, IR, Marketing and Communications, tel. +358 40 502 4697

Kalmar

Attachments

  • CV Casimir Lindholm_en (https://ml-eu.globenewswire.com/Resource/Download/ab503a2b-5606-4822-a590-23ea0a10c8d1)
  • lindholm-casimir (https://ml-eu.globenewswire.com/Resource/Download/523c4c5c-233c-4246-bc2f-a917efb79fdb)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.